PMID: 8035779Feb 23, 1994

Myofibrillar adaptations during cardiac hypertrophy

Molecular and Cellular Biochemistry
R L Toffolo, C D Ianuzzo


The main purpose of this study was to determine the transmural adaptive changes that occur in cell size, myofibrils, and myosin isoforms from the endocardium (ENDO) to the epicardium (EPI) of the left ventricle (LV) of the rat heart during compensatory hypertrophy. Hypertrophy was induced by supra-renal aortic constriction for periods of 2, 7, 15 and 30 days. Percent left ventricular hypertrophy averaged 63 +/- 9.7% at 30 days following constriction. A significant (p < 0.05) transmural gradient in the V3 myosin isoform (9 +/- 0.7% ENDO vs. 5 +/- 1.8% EPI) was initially observed at 7 days and was still evident by 30 days (25 +/- 3.6% ENDO vs 15 +/- 2.0% EPI). Cell cross-sectional area was also greater (p < 0.05) in the ENDO than in the EPI at 7, 15 and 30 days. MF diameter was determined only at 30 days and was found to be similar to control values in both the hypertrophied ENDO (sham 1.24 +/- 0.05 vs hyp 1.18 +/- 0.09 microns) and EPI (sham 1.17 +/- 0.08 vs hyp 1.06 +/- 0.08 microns). The combined effects of cardiac myocyte hypertrophy with no change in MF diameter resulted in a calculated increase of approximately 70% in the number of myofibrils per myocyte both in the ENDO and EPI. It was concluded that the adaptive strategy ...Continue Reading


Feb 22, 2011·Pflügers Archiv : European journal of physiology·Olivier Cazorla, Alain Lacampagne
Sep 29, 1999·International Journal of Cardiology·A DeligiannisA Coats
Nov 18, 1998·Fundamental & Clinical Pharmacology·C CommunalP Demenge
Feb 17, 2007·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·Andrea P Babick, Naranjan S Dhalla
May 17, 2006·Journal of Cardiovascular Pharmacology and Therapeutics·Naranjan S DhallaRamesh K Goyal
Jun 29, 2004·Journal of Applied Physiology·Cynthia A CarnesPeter J Reiser
Aug 22, 2001·American Journal of Physiology. Heart and Circulatory Physiology·J R ForderS J Blackband


Nov 1, 1979·Nature·A M LompréB Swynghedauw
Nov 1, 1978·Scandinavian Journal of Clinical and Laboratory Investigation·F Kiil
Apr 1, 1991·Circulation Research·S E CampbellK Rakusan
Jan 1, 1987·Journal of Cardiovascular Pharmacology·R JacobM Vogt
Nov 1, 1989·Chromosoma·P B Moens, W C Earnshaw
May 1, 1989·Basic Research in Cardiology·S E CampbellA M Gerdes
Aug 1, 1986·The Anatomical Record·A M GerdesS P Bishop
Sep 1, 1970·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·M H Brooke, K K Kaiser
Mar 1, 1973·The American Journal of Physiology·L A SordahlA Schwartz
Jan 1, 1969·Journal of Ultrastructure Research·A R Spurr
Aug 1, 1981·Circulation Research·J J MercadierK Schwartz
Jan 1, 1981·Journal of Immunological Methods·G D Johnson, G M Nogueira Araujo
Jul 1, 1963·The Journal of Cell Biology·G W RICHTER, A KELLNER
Aug 1, 1964·The American Journal of Physiology·E S KIRK, C R HONIG

Related Concepts

Immunofluorescence Assay
Left Ventricular Hypertrophy
Actomyosin Adenosinetriphosphatase
Cell Volume
Cardiomyopathy, Hypertrophic, Familial
Rats, Holtzman

Related Feeds


Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.